Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-10-25

Clinical Trial Update: A Study of LNK01001 Capsule in Moderately to Severely Active Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

Phase 2 study update for LNK01001 capsule in moderately to severely active rheumatoid arthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LNK01001

Snippet

Sponsor: Lynk Pharmaceuticals Co., Ltd | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED